Business
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial
About this update from Enliven Therapeutics, Inc.
[{"type":"text","content":"Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial\n Reported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical outcomes in an Open Label Extension Study that tests IMR-687 for longer duration IMR-687 granted Orphan Drug, Fast Track and Rare Pediatric designations by the FDA for beta-thalassemia Company to host conference call and live webcast today at 8:30 a.m. ET BOSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business highlights. “As we head into the second half of 2020, we are encouraged by several advancements across our programs that bring us closer to providing oral treatment options to patients with rare blood disorders,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “We initiated our Phase 2b clinical trials for IMR-687 in both sickle cell disease and beta-thalassemia and dosed the first patient in our Ardent Phase 2b clinical trial for adult patients with sickle cell disease. We also reported encouraging Phase 2a interim clinical trial results with IMR-687 at the European Hematology Association Annual Congress and more recently observed promising clinical outcomes with longer duration IMR-687 treatment as part of our Phase 2a open label extension trial. In addition, we made important progress on the regulatory front as we were granted Orphan Drug, Fast Track and Rare Pediatric designations by the FDA for the treatment of patients with beta-thalassemia. Finally, we are leveraging IMR-687’s differentiated mechanism of action and began preclinical studies to explore its potential for the treatment of heart failure with preserved ejection fraction, or HFpEF.” Dr. Ballal continued, “We look forward to further advancing patient recruitment activities for our Phase 2b clinical trials and expect to report top-line data from our ongoing Phase 2a clinical trial in sickle cell disease during the fourth quarter of 2020.” Recent Corp...